Project Grant R01CA300719
Award Date 5/18/26
Completion Date 4/30/31
Dollars Obligated $617K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Medical University of South Carolina a $643,053 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, with completion anticipated by April 30, 2031. This five-year award supports fundamental research investigating the novel functions of cyclin D3 in T cell regulation and tumor progression. The research focuses on addressing critical challenges in T cell-based immunotherapy for...
- Federal Project Grant Award Summary The Medical University of South Carolina received a $153,768 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective September 10, 2025, through July 31, 2028. This award supports research training and investigator development focused on elucidating the role of peroxisome biogenesis in enhancing anti-tumor T cell metabolic fitness and immune function. The grant funds a research initiative...
- Federal Grant Award Summary The Medical University of South Carolina received a $388,256 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective September 1, 2025 through August 31, 2027. This award supports research investigating the biologic rationale for fallopian tube removal as a preventive intervention against uterine serous carcinoma (USC), a highly aggressive form of uterine cancer responsible for 40% of endometrial...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded Columbia University's Health Sciences Division a $501,422 Project Grant effective May 1, 2026, through April 30, 2031, to advance research on synthetic lethal (SL) targeting in cancer. This research builds upon the institution's established expertise in identifying and characterizing SL drug targets and seeks to validate and mechanistically characterize the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $701,330 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective June 11, 2025, with completion scheduled for May 31, 2030. This award supports the development of selective inhibitors targeting SETD8 (lysine methyltransferase Set8), specifically designed to treat multiple myeloma, an incurable plasma cell malignancy. The research focuses on developing...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $323,860 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) on August 18, 2025, with completion targeted for April 30, 2028. This award supports research investigating the role of mutagenic DNA repair pathways in cancer cell persistence and acquired drug resistance. The project focuses on understanding how cancer cells under stress from anti-cancer...
- Federal Grant Award Summary The National Cancer Institute awarded $727,732 to Sloan-Kettering Institute for Cancer Research on June 3, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a Phase IB/II clinical trial investigating combination therapy for dedifferentiated liposarcoma (DDLS). The primary deliverable is a clinical trial evaluating the efficacy and safety of palbociclib combined with the MEK inhibitor mirdametinib in patients with progressive DDLS, with an...